Cross-source evidence timeline
Pemvidutide research timeline
Follow 4 selected, directly cited source records from March 20, 2026 through July 31, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT06987513↗
PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT05989711↗
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
Pemvidutide IMPACT study record updated↗
ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.↗
Added to PeptideScanner July 22, 2026Clinical trials
ClinicalTrials.gov record NCT07009860↗
PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
Added to PeptideScanner August 14, 2026